This Pre-Solicitation opportunity from Department Of Health And Human Services was posted on May 1, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
NOI to Sole Source to QuVa Pharma, Inc.
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The National Institutes of Health plans to award a one-year, firm-fixed-price sole source contract to QuVa Pharma, Inc. for the purchase of 503b-compounded intravenous narcotics essential for patient care at the NIH Clinical Center in Bethesda, Maryland. Market research identified QuVa Pharma as the only U.S. manufacturer and distributor of these specialized IV narcotics, with no alternative suppliers capable of meeting the clinical requirements, justifying a non-competitive acquisition under FAR 6.302-1. This action is conducted under Simplified Acquisition Procedures (FAR Part 13), which exempts it from full and open competition requirements due to the uniqueness of the product and the limited market. The total estimated value of the contract is $684,000 over five years, including one base year valued at $110,000 and four optional years. Delivery and performance are required exclusively at the NIH Clinical Center, with inspection and acceptance managed by the government’s Contracting Officer’s Representative. The contract relies on QuVa Pharma’s FDA-registered 503b compounding status to ensure compliance with federal pharmaceutical standards, though detailed packaging, labeling, preservation, or inspection protocols are not specified in the documentation. No solicitation will be issued, and no formal competitive evaluation factors, pricing breakdowns, or clause attachments are required or provided beyond the statutory justification for sole source procurement. Public comments on the intent to award are being accepted until May 6, 2026, but the government retains sole discretion to proceed without competition.
General Info
Agency
NAICS
Place of Performance
Bethesda, MD, 20892, USASet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
The purpose of this acquisition is to purchase 503b compounded Intravenous (IV) Narcotics for patient care. Market research has been conducted with only two responses, from QUVA, the known Compounder and distributor for these IV narcotics. Through trade shows, continuous learning seminars and trade journals, the CC Pharmacy Department stays abreast of the industry and is current on the availability of singular distribution outlets for these medications.
• Product Service Code: 6515 – Medical and Surgical Instruments, Equipment, and Supplies
• NAICS Code: 325412 – Pharmaceutical Preparation Manufacturing
• Place of Performance: NIH Clinical Center, Bethesda, MD 20892 USA
POTS: 26-000038
Description:
This is a notice of intent, not a request for a quotation. A solicitation document will not be issued, and quotations will not be requested.
The National Institutes of Health (NIH) intends to award a one-year contract to QuVa Pharma, Inc., located at 3 Sugar Creek Center Boulevard, Sugarland, TX 77478, on a firm fixed price sole source award basis for the purchase of 503b compound Intravenous (IV) Narcotics for patient care.
The proposed vendor, QuVa Pharma Inc., is the Original Manufacturer and has not designated other distributors of IV narcotics in the U.S.
This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.
The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government.
Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Huda Malik, Contract Specialist via email to huda.malik@nih.gov by May 6, 2026 at 9 am EST.
More opportunities from Department Of Health And Human Services → National Institutes Of Health Olao
Same awarding agency
Find Active Opportunities Like This
Get AI-powered intelligence on the opportunities still open
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 650+ contractors already using CLEATUS